Kornimate/medical-research-clean huggingface dataset:
hippocampal-avoiding whole brain irradiation with simultaneous integrated boost for treatment of brain metastases

Conditions: Brain Neoplasms, Adult, Malignant

Summary: the investigators hypothesize that avoidance of the hippocampal region with wbrt (whole-brain radiotherapy ) may delay or reduce the onset, frequency, and/or severity of ncf (neurocognitive function) decline, as measured with clinical neurocognitive tools.

we propose to use conformal avoidance of the hippocampal region during whole brain radiotherapy to reduce the dose to the hippocampi, thereby putatively limiting the radiation-induced inflammation of the hippocampal region and subsequent alteration of the microenvironment of the neural progenitor cells

Eligibility criteria:
inclusion criteria: 1. pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy.. direct biopsy of cns (central nervous system) lesions is not necessarily required although could constitute an allowed site of tissue confirmation as medically prudent. patients who have been disease free for more than 5 years prior to the appearance of cns metastases should undergo repeat biopsy of either a systemic metastasis or the cns metastases to confirm the recurrent malignancy. 2. patients with measurable brain metastasis outside a 5-mm margin around either hippocampus 3. patients with measurable brain metastasis who have not been or will not be treated with srs (stereotactic radiosurgery ) or surgical resection (note: these treatment options are only permitted at relapse) 4. history/physical examination within 28 days prior to registration 5. patients must fall into rtog (radiation therapy oncology group) recursive partitioning analysis (rpa) class i or ii 6. patients must have a life expectancy of at least 4 months. 7. age ≥ 18 years 8. karnofsky performance status ≥ 70 9. patients must provide study-specific informed consent prior to study entry 10. women of childbearing potential and male participants must practice adequate contraception 11. women of childbearing potential must have a negative, qualitative serum pregnancy test ≤2 weeks prior to study entry exclusion criteria: 1. patients with greater than 9 discrete metastases on mri. 2. patients with leptomeningeal metastases 3. patients with measurable brain metastasis not resulting from small cell lung cancer and germ cell malignancy 4. plan for chemotherapy or targeted therapies during wbrt or over the subsequent 7 days 5. contraindication to mr (magnetic resonance) imaging such as implanted metal devices or foreign bodies, severe claustrophobia and patients unable to receive gadolinium contrast agents 6. serum creatinine \> 1.4 mg/dl ≤ 28 days prior to study entry 7. prior radiation therapy to the brain 8. patients planning to undergo radiosurgery to any cns lesion or patients planning to have surgical resection of all of their cns lesions
heart rate variability of patients with bipolar disorder in subsyndromal depressive phase

Conditions: Bipolar Disorder; Subsyndromal Depressive Phase; Heart Rate Variability

Summary: the purposes of this study were: (1) to compare heart rate variability between bipolar patients in subsyndromal depressive phase and healthy controls (2) to evaluate the relation between the severity of subsyndromal depressive symptoms and reduced heart rate variability.


Eligibility criteria:
inclusion criteria: 1. bipolar group: * dsm-iv bipolar disorder * montgomery-åsberg depression rating scale (madrs) score for last one month : ≤ 10 * clinical global impression severity (cgi-s) for last one month : ≤ 3 2. healthy controls group: subjects had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist. exclusion criteria: * psychiatric disorder except bipolar disorder * neurological symptoms or signs * history of head trauma * history of cardiovascular diseases * any medication except psychiatric medication.
gcf levels of il-1β and il-6 in gingivitis and stage iii-grade c periodontitis

Conditions: Periodontitis

Summary: periodontal diseases are chronic diseases that occur as a result of a violation of the balance between microbial dental plaque and the host response. gingivitis is a disease characterized by inflammation of the gingiva that occurs in one or more areas without loss of attachments.1 in periodontitis, an inflammatory event that begins in the gingiva along with gingivitis spreads to the periodontal ligament, alveolar bone and soft tissues that support the tooth, causing the destruction of these structures.2 cytokines are low molecular weight proteins that participate in the initial and active stages of inflammation and immunity. in periodontal disease pathogenesis, cytokine response has been reported to play a very critical role in determining disease progression.3 il-1beta and il-6 are key cytokines in chronic inflammatory diseases and have the potential to initiate bone loss and tissue destruction seen in periodontal disease.4the purpose of this study; it is to determine the degree of inflammation and periodontal destruction by determining the levels of il-1beta and il-6 cytokines in the gingival crevicular fluid of periodontal healthy and diseased individuals.

periodontal measurement were done at 6 sites per tooth after clinical evaluation, individuals were divided into 3 groups 1. healthy control groups: clinically healthy gingiva 2. gingivitis groups: bop score of 10% or greater and pd≤3mm 3. periodontitis groups: al ≥5 mm, pd≥6 mm and tooth loss due to periodontitis of ≤4. gcf samples were collected using strips.

Eligibility criteria:
inclusion criteria: * have periodontitis * have 16 permanent teeth exclusion criteria: * systemic disease * using drugs

Keywords: periodontal disease periodontitis gingivitis cytokines
study of abt-869 in subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib

Conditions: Advanced Renal Cell Carcinoma

Summary: this study is designed to determine the clinical efficacy and toxicity of abt 869 in the treatment of subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib.


Eligibility criteria:
inclusion criteria * subject has undergone previous nephrectomy. * subject has received at least 2 cycles (12 weeks) of treatment with sunitinib for rcc and stopped therapy due to progressive disease within 100 days prior to screening. * subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a ct scan as defined by recist. * ecog performance score of 0-1. * no history of another active cancer within the past 5 years.life expectancy of at least 4 months. * willing to take adequate measures to prevent pregnancy. exclusion criteria * subject has received anti-cancer therapy within 21 days or within a period defined by 5 half lives, whichever is shorter, prior to study drug administration. * subject has untreated brain or meningeal metastases. * subject has received a tyrosine kinase inhibitor (tki) other than sunitinib or sorafenib. * prior use of avastin is allowed. * the subject is receiving therapeutic anticoagulation therapy. * the subject has a history of/or currently exhibits clinically significant cancer related events of bleeding (e.g., hematuria, hemoptysis). * the subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (bp) \> 100 mmhg; or systolic blood pressure (bp) \> 150 mmhg. * the subject has a history of myocardial infarction within 6 months of study day 1. * the subject has a documented left ventricular (lv) ejection fraction \< 50%. * the subject has known autoimmune disease with renal involvement (eg, lupus). * female subjects who are pregnant or breast feeding. * subject is receiving anti-retroviral therapy for hiv. * subject has a clinically significant uncontrolled condition(s) including but not limited to: * active uncontrolled infection, * class iii or iv heart failure as defined by the new york heart association functional classification system, * unstable angina pectoris or cardiac arrhythmia, * history of adrenal insufficiency, * psychiatric illness/social situation that would limit compliance with study requirements; * active, ulcerative colitis, crohn's disease, celiadisease or any other conditions that interfere with absorption. * subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.
bnp measurement reduces resource utilization for patients with chf admitted thorough the ed

Conditions: Congestive Heart Failure

Summary: measurement of brain natriuretic peptide (bnp) in dyspneic patients increases diagnostic accuracy for congestive heart failure (chf). limited information is available regarding economic outcomes attributable to bnp assay. the aim of this study was to assess the economic impact of bnp assay in elderly dyspneic patients presenting to the emergency department (ed).

dyspneic patients 65 years were enrolled in a randomized, controlled trial; hemodynamically unstable patients were excluded. bnp (biosite assay) levels were measured prior to physician assessment with randomization in 1:1 ratio to either bnp 1) level reported or 2) level not reported. ed physicians made triage decisions guided by clinical judgment and nomogram to aid in interpretation of bnp level. primary outcome was mean total hospital cost per subject. secondary outcomes included admission rate, service assignment, discharge diagnosis and length of stay. differences between groups were compared by t-test with bootstrap. costs reflect 2005 constant dollars.

Eligibility criteria:
inclusion criteria: * dyspneic patients 65 years or older presenting to the ed with chief complaint of shortness of breath. exclusion criteria: * hemodynamically unstability

Keywords: congestive heart failure brain naturietic peptide hospital utilization cost
safety and efficacy study of gevokizumab to treat non-infectious uveitis controlled with systemic treatment

Conditions: Uveitis

Summary: the purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one eye * controlled uveitic disease in both eyes * stable dose of oral corticosteroids in combination with selected stable immunosuppressive therapy * effective contraceptive measures exclusion criteria: * infectious uveitis and masquerade syndromes * isolated anterior uveitis * contraindication to mydriatics * active tuberculosis disease * history of allergic or anaphylactic reactions to monoclonal antibodies * history of recurrent infection or predisposition to infection; active ocular infection * pregnant or nursing women other protocol-defined inclusion/exclusion criteria may apply

Keywords: uveitis non-infectious uveitis intermediate uveitis posterior uveitis panuveitis
novel therapies for metabolic complications of lipodystrophies

Conditions: Insulin Resistance; Hypertriglyceridemia; Diabetes; Hepatic Steatosis

Summary: lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue loss. the purpose of the study and it's four subprojects is to examine the safety and efficacy of various novel interventions designed to improve or resolve the fatty liver, hypertriglyceridemia, and insulin resistance or diabetes that is seen in these patients.

we propose novel therapeutic approaches for the management of metabolic complications in patients with lipodystrophies. the four interventions to be tested are: hypothesis 1: an extremely low fat diet.

Eligibility criteria:
inclusion criteria: general inclusion criteria: * patients with lipodystrophies as diagnosed by clinical criteria * any one of the following: * diabetes mellitus, or * fasting serum triglycerides greater than 200 mg/dl, or * fasting serum insulin greater than 30 u/ml, or * hepatic steatosis ( greater than 5.6% hepatic triglyceride content) as demonstrated by 1h mrs. exclusion criteria: * known liver disease due to causes other than non-alcoholic steatohepatitis: * current alcohol abuse (more than 7 drinks or 210 g per wk for women and more than 14 drinks or 420 g per wk for men). * positive serological markers of hepatitis b and c. * autoimmune hepatitis, autoimmune cholestatic liver disorders, wilson disease and alpha-1-antitrypsin deficiency as indicated by clinical and laboratory tests. * drug-induced liver disease * evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml and/or liver mass on imaging study suggestive of liver cancer. * decompensated liver disease as evidenced by clinical features of hepatic failure (variceal bleeding, ascites, hepatic encephalopathy etc.) and laboratory investigations (prolonged prothrombin time, hypoalbuminemia, presence of esophageal varices etc.) * use of the drugs which can potentially decrease hepatic steatosis during previous 3 months; high-dose vitamin e, betaine, acetylcysteine, choline and probucol. * significant systemic or major illnesses other than liver disease (congestive heart failure, unstable angina, cerebrovascular disease, respiratory failure, renal failure \[serum creatinine more then 2 mg/dl\], acute pancreatitis, organ transplantation, serious psychiatric disease, and malignancy) that could interfere with the trial and adequate follow up. * acute medical illnesses precluding participation in the studies. * known hiv infected patient. * current substance abuse. * pregnant or lactating women. * hematocrit of less than 30%. * history of weight loss ( more than 10%) or use of weight loss drugs such as sibutramine or orlistat in the last 3 months. each subproject has additional specific inclusion and exclusion criteria

Keywords: lipodystrophy
safety and dose ranging study of insulin receptor moab-ids fusion protein in patients with hunter syndrome

Conditions: Mucopolysaccharidosis II

Summary: agt-182 is a fusion protein containing idursulfase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. this study is a safety and dose ranging study to obtain safety and exposure data, as well as information on the biological activity of the investigational drug.

this is a sequential, open-label, dose escalation, multi-dose study in adults with hunter syndrome. two dose levels, assuming tolerability, are planned sequentially, with safety data from the previous cohort being reviewed prior to escalation to the next higher dose cohort. subjects will receive weekly doses of agt-182 for 8 weeks if ert-naive or agreeing to a 6-week ert washout, or for 13 weeks if currently taking ert and not agreeing to washout.

Eligibility criteria:
inclusion criteria: * male age 18 years or older * diagnosis of hunter syndrome (documented fibroblast or leukocyte ids enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory - or any level of enzyme deficiency together with the presence of a pathogenic mutation in the ids gene - and documentation of normal enzymatic activity of at least 1 other sulfatase.) * must fall into one of the following groups: * currently receiving standard enzyme replacement therapy (ert) and be willing to discontinue it for the study duration, taking agt-182 instead * have not received standard ert for at least 3 months and have elevated ugags of at least 3.5 fold above age-related normals at study screening * have never received ert * voluntary written consent * sexually mature males must be advised to use a medically accepted method of contraception throughout the study. exclusion criteria: * refusal to complete screening/baseline evaluations * receipt of an investigational drug within the prior 90 days * any medical condition or other circumstances that may significantly interfere with study compliance * clinically significant spinal cord compression, evidence of cervical instability * known hypersensitivity to idursulfase or any of the components of agt-182 * known to be nonresponsive to standard ert treatment (i.e., high ugag values despite taking full dose standard ert) * history of diabetes mellitus or hypoglycemia * contraindication to lumbar puncture, if the patient agrees to this optional assessment

Keywords: mps ii hunter syndrome
comparison of diagnostic accuracies of various endoscopic examination techniques

Conditions: Colorectal Cancer

Summary: endoscopic diagnosis of lateral spreading tumours (lst) with submucosal invasion is important in guiding the treatment strategy. the use of advanced imaging is not standard clinical practice in china. a clinical trial is now under way comparing the accuracy of narrow band imaging (nbi), endoscopic ultrasonography (eus) and magnifying chromoendoscopy (mce) for the diagnosis of lst with submucosal invasion.

endoscopic diagnosis of lateral spreading tumours (lst) with submucosal invasion is important in guiding the treatment strategy. the use of advanced imaging is not standard clinical practice in china. a clinical trial is now under way comparing the accuracy of narrow band imaging (nbi), endoscopic ultrasonography (eus) and magnifying chromoendoscopy (mce) for the diagnosis of lst with submucosal invasion.the final histologic diagnosis was used as the true diagnosis in the present study. by comparing the consistency of histologic diagnosis and preoperative evaluation,the diagnostic accuracies of various endoscopic examination techniques(narrow band imaging , endoscopic ultrasonography , and magnifying chromoendoscopy) was calculated respectively.

Eligibility criteria:
inclusion criteria: - patients older than 18 years and less than 65 years patients with endoscopic diagnosis of lateral spreading tumours signed informed consent exclusion criteria: - patients with serious heart, brain, lung, kidney complications patients with intestinal obstruction previous therapy for colorectal cancer women in gestational and lactational period taking anticoagulants or antiplatelet medications. based on the evaluations of physicians, the patient's condition is not suitable for the clinical trial
virtual weight management shared medical visit

Conditions: Metabolic Syndrome; Obesity

Summary: culinary medicine has emerged which provides the practical application of nutrition education through experiential learning. studies have shown that patients with metabolic syndrome who underwent a series of classes that featured nutrition recommendations and cooking classes had weight loss, and improved cardiac health and blood sugar management. given the increasing focus on providing remote experiences to minimize contact and risk of infection with sars-cov2, this pilot study at boston medical center (bmc) will integrate a physician consultation, interactive didactic presentations, nutritious cooking and mind- body exercises. patients with obesity and metabolic syndrome can attend a virtual shared medical visit series co-taught by a registered dietician and chef and an endocrinologist and weight management specialist. data will be collected in the form of surveys, phone interviews, chart review, and home monitoring to test both the feasibility of running such an intervention virtually and to explore whether attending this one month program with weekly remote classes/visits improves vitals including weight and blood blood pressure and other small habit changes in patients.


Eligibility criteria:
inclusion criteria: * english speaking * bmi =\> 30 * must have documented measured blood pressure, weight, height in the 12 months prior to the intervention * enrolled in boston medical center's (bmc's) food pantry program exclusion criteria: * patients with advanced dementia or uncontrolled psychiatric disease * uncontrolled medical illness including severe hypertension, recent acute coronary syndrome, active malignancy or other condition that would make the subject unable to complete the study procedures

Keywords: culinary medicine teaching kitchens virtual shared medical appointments (sma) mind body exercises social determinants of health (sdoh)
platelet rich plasma for insufficient endometrium

Conditions: Infertility of Uterine Origin

Summary: to determine the effectiveness of an intrauterine prp infusion on endometrial thickness and in vitro fertilization (ivf) outcomes in a population of infertile women with a history of unresponsive thin endometrium.

patients with a history of thin endometrium will be randomized to either an intrauterine infusion of prp vs. a placebo infusion of normal saline. this is a double-blind, placebo controlled prospective rct. patients will then proceed with a frozen embryo transfer of a single euploid embryo per routine.

Eligibility criteria:
inclusion criteria: * patients who have previously undergone at least 2 unsuccessful frozen embryo transfer cycles, defined as failure to achieve a sustained clinical pregnancy (visualization of intrauterine gestational sac on ultrasound or a cancelled embryo transfer cycle due to inadequate endometrial thickness * patients with a diagnosis of thin endometrial lining (less than or equal to 6 mm maximum thickness) during prior unsuccessful or canceled embryo transfer cycles. exclusion criteria: * fewer than 2 prior unsuccessful or canceled frozen embryo transfer cycles. * most recent unsuccessful embryo transfer prior to january 1, 2017. * mullerian anomalies, excluding arcuate uterus * concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery * communicating hydrosalpinx without plans for surgical correction prior to study enrollment. * failure of patient to agree to enrollment in study with written consent. * concurrent pregnancy * anticoagulation use for which plasma infusion is contraindicated * history of thrombosis * thrombophilia either inherited or acquired * concomitant use of adjunctive therapies for proliferation. these must be discontinued upon enrollment. * embryo planned to be used for transfer generated from surgically obtained sperm due to a diagnosis of non-obstructive azoospermia * recurrent/persistent endometrial fluid in prior cycles